Echinacea biotechnology: advances, commercialization and future considerations by Parsons, J.L. (Jessica L.) et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=iphb20
Pharmaceutical Biology
ISSN: 1388-0209 (Print) 1744-5116 (Online) Journal homepage: https://www.tandfonline.com/loi/iphb20
Echinacea biotechnology: advances,
commercialization and future considerations
Jessica L. Parsons, Stewart I. Cameron, Cory S. Harris & Myron L. Smith
To cite this article: Jessica L. Parsons, Stewart I. Cameron, Cory S. Harris & Myron L. Smith
(2018) Echinacea biotechnology: advances, commercialization and future considerations,
Pharmaceutical Biology, 56:1, 485-494, DOI: 10.1080/13880209.2018.1501583
To link to this article:  https://doi.org/10.1080/13880209.2018.1501583
© 2018 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 10 Oct 2018.
Submit your article to this journal 
Article views: 432
View Crossmark data
Citing articles: 1 View citing articles 
REVIEW ARTICLE
Echinacea biotechnology: advances, commercialization and future considerations
Jessica L. Parsonsa,b, Stewart I. Cameronc, Cory S. Harrisa,d and Myron L. Smitha,b
aOttawa-Carleton Institute of Biology, Ottawa, ON, Canada; bDepartment of Biology, Carleton University, Ottawa, ON, Canada; cWood Science
and Technology Centre, Hugh John Flemming Forestry Centre, Fredericton, NB, Canada; dDepartment of Biology, University of Ottawa, Ottawa,
ON, Canada
ABSTRACT
Context: Plants of the genus Echinacea (Asteraceae) are among the most popular herbal supplements on
the market today. Recent studies indicate there are potential new applications and emerging markets for
this natural health product (NHP).
Objective: This review aims to synthesize recent developments in Echinacea biotechnology and to iden-
tify promising applications for these advances in the industry.
Methods: A comprehensive survey of peer-reviewed publications was carried out, focusing on Echinacea
biotechnology and impacts on phytochemistry. This article primarily covers research findings since 2007
and builds on earlier reviews on the biotechnology of Echinacea.
Results: Bioreactors, genetic engineering and controlled biotic or abiotic elicitation have the potential to
significantly improve the yield, consistency and overall quality of Echinacea products. Using these technol-
ogies, a variety of new applications for Echinacea can be realized, such as the use of seed oil and anti-
microbial and immune boosting feed additives for livestock.
Conclusions: New applications can take advantage of the well-established popularity of Echinacea as a
NHP. Echinacea presents a myriad of potential health benefits, including anti-inflammatory, anxiolytic and
antibiotic activities that have yet to be fully translated into new applications. The distinct chemistry and
bioactivity of different Echinacea species and organs, moreover, can lead to interesting and diverse com-
mercial opportunities.
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Introduction
Biotechnology centred on species of Echinacea Moench
(Asteraceae) has grown substantially in recent decades, owing
to the popularity of Echinacea as a natural health product
(NHP). Originating in North America and part of the trad-
itional pharmacopeia of Indigenous Peoples (Moerman 1998),
Echinacea is now cultivated around the world and has an
annual global market value estimated at approximately $1.3
billion (Blumenthal et al. 2003). Despite alternative taxono-
mies based on molecular, morphometric and phytochemical
variation (Binns et al. 2002a), the traditional taxonomy of
McGregor (1968) is still widely used and, recently supported
by chloroplast genome data (Zhang et al. 2017), recognizes
nine species within the genus. Commercial Echinacea prepara-
tions contain one or as many as three different species: E. pur-
purea (L.) Moench, E. angustifolia DC., and less frequently, E.
pallida (Nutt.) Nutt., with E. purpurea making up about 80%
of commercial production. Other recognized taxa, E. laevigata
(C. L. Boynton and Beadle) S. F. Blake, E. atrorubens Nutt., E.
paradoxa Norton, E. sanguinea Nutt., E. simulata McGregor
and E. tennesseensis (Beadle) J. K. Small, are far less abundant
and rarely utilized compared to the commercial species
(McKeown 1999). Whereas the commercial species have
received extensive research attention, these other Echinacea
taxa have received almost none.
Currently popular as an immune stimulant, Echinacea species
were used by North American Indigenous Peoples as a treatment
for throat infections, wounds and pain, and was historically used
in Eclectic medicine for septic conditions (Shemluck 1982).
Related pharmacological activities and therapeutic uses continue
to be explored, including anti-inflammatory, analgesic, anxiolytic
and antimicrobial activities (Hostettmann 2003; Abbasi et al.
2007a; Haller et al. 2013; Cruz et al. 2014; Shin et al. 2014). The
main bioactive compounds present in Echinacea extracts are the
phenolics, alkylamides and polysaccharide/glycoproteins (Figure
1). The phenolics include echinacoside, cynarin, cichoric acid,
caftaric acid and chlorogenic acids (CADs), and possess anti-
microbial and antioxidant activity. The alkylamides are a group
of more than 30 lipophilic compounds with anti-inflammatory
properties mediated through activation of the endocannabinoid
system, exhibit antifungal properties and inhibit cyclooxygenase
and lipoygenase enzyme activities. Polysaccharides/glycoproteins
include complex carbohydrate moieties such as arabinogalactans
that act as immunostimulants. Barnes et al. (2005) give a thor-
ough inventory of bioactive compounds isolated from Echinacea
and new activities continue to be reported and reviewed (Cruz
et al. 2014; Murthy et al. 2014; Manayi et al. 2015).
Differences in the composition and content of bioactive phy-
tochemicals are inherent to Echinacea taxa (Figure 2). For
example, E. purpurea roots completely lack echinacoside, a
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common constituent in the roots of other Echinacea species, but
have very high levels of certain alkylamides, of which only trace
amounts are found in the roots of other species (Sloley et al.
2001; Binns et al. 2002b; Murch et al. 2006). Typically, there can
be significant variation in the phytochemistry of populations
and/or individuals of the same species as well, particularly in E.
angustifolia, for which there are established chemoraces (Kapteyn
et al. 2002; Binns et al. 2002c; Liu et al. 2006; Chuang et al.
2010; Abbasi et al. 2012). Additionally, in all Echinacea species
studied to date, the localization and content of active metabolites
changes over time, both seasonally and with plant age, and varies
between plant parts (Figure 2) (Choffe et al. 2000; Binns et al.
2002b). The most recent study on the localization of alkylamides
in E. purpurea examined alkylamide content in a total of 36 tis-
sues (Rizhsky et al. 2016), not including the seed. Particularly
high concentrations of alkylamides were found in petals and disc
flowers, and moderate concentrations were noted in receptacles
of mature flower heads. Our group recently observed that the
glands on the outer surface of Echinacea seeds (beneath the
perianth) are also enriched in alkylamides (Parsons et al. 2018).
E. purpurea and E. angustifolia roots and flower heads generally
have the highest concentrations of bioactive compounds, whereas
the leaves and stems have low concentrations of metabolites, and
are rarely used in preparing NHPs (Kabganian et al. 2003; Qu
et al. 2005; Chen et al. 2009). However, ascorbic acid (vitamin
C) accumulates in the leaves, which could augment immune
functions (Zagumennikov et al. 2015). This pattern of localiza-
tion differs from E. paradoxa, where phytochemicals are concen-
trated more in the flower heads (Chen et al. 2009), and may
differ in other rare species as well. This variation potentially pro-
vides a basis for selective breeding programs, selection of useful
cultivars, and multiple product streams from different parts of
the same plant.
Despite the success of Echinacea on the market, challenges
such as fungal pathogens, seed dormancy, low germination rates
and a relatively long maturation time still pose problems for the
industry, with the biggest challenge being product standardiza-
tion (Liu et al. 2006; Zheng et al. 2006; Abbasi et al. 2007a;
Figure 1. Structures of Echinacea phytochemicals with established bioactivity. Caffeic acid derivatives are represented by caffeic acid, chlorogenic acid, caftaric acid
(left) as well as cichoric and echinacoside (middle). Echinacea alkylamides are represented by the isomers of 2,4,8,10-dodecatetraenoic acid isobutylamide; a diversity
of alkylamides in Echinacea are similarly isobutylamides with alkyl chains of variable length and saturation.
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Figure 2. Localization of bioactive compounds in E. purpurea, E. angustifolia, E. pallida, and E. paradoxa. Compounds in bold are present at high concentrations; italics
indicate compounds found in trace amount (Sloley et al. 2001; Binns et al. 2002b; Kabganian et al. 2003; Stuart and Wills 2003).
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Kindscher et al. 2008; Maggini et al. 2012). Different commercial
brands use diverse genotypes, plant parts and blends as well as
different growing conditions, harvesting times and extraction
methods, leading to qualitative and quantitative inconsistencies
in bioactive compounds composition (Stuart and Wills 2003;
Abbasi et al. 2007a; Jones et al. 2009). As industry faces these
challenges, research has focused on finding ways to meet a
strong demand for consistent, high-quality Echinacea products.
In this article, we review the most promising developments and
trends in Echinacea biotechnology, focusing on propagation,
standardization and optimization of both the production process
and the quality of plant material. We will examine advantages
and disadvantages of the various technologies, and highlight
future applications focusing on diversification and sustainability
of the Echinacea industry.
Echinacea production in bioreactors
Traditionally, Echinacea has been propagated by seed, crown div-
ision or root cuttings but these processes are time-consuming,
have limited propagation potential for producing large numbers
of plants and can produce genetically variable plant material.
Tissue culture methods – growing plants in vitro – have the
potential to solve a number of the problems related to Echinacea
propagation, including cultivation bottlenecks, the use of rare
species and product standardization. Owing to the rapid develop-
ment of tissue culture technology, a large – yet fragmented –
body of research has accumulated on its application
in Echinacea.
In vitro micropropagation techniques, such as adventitious
root and shoot culture, and somatic embryogenesis, can produce
hundreds of clonal plants from cuttings of a parent plant. Abbasi
et al. (2007a) provide a thorough review of micropropagation
techniques in Echinacea, all of which allow for more consistent
secondary metabolite profiles associated with isogenic lines, year
round cultivation and reduction of microbial contamination.
Micropropagation can also be used to create plants having
unique phytochemical profiles by culturing different parts of a
parent plant. For example, shoots regenerated from E. angustifo-
lia flower stalks have proportionately higher content of CADs
compared to shoots generated from leaf explants (Lucchesini
et al. 2009). Somatic embryogenesis by tissue culture, and to a
lesser extent organogenesis, can induce genetic changes (Chuang
et al. 2009) – a phenomenon called somaclonal variation.
Micropropagation has been accomplished with E. purpurea, E.
pallida, E. angustifolia and E. tennesseensis where, as expected,
clonal plants have similar phytochemical profiles, showing only
minor somaclonal variation (Abbasi et al. 2007a; Moraes et al.
2011; Butiuc-Keul et al. 2012 for additional studies). Although
micropropagation provides a rapid way to generate plants, the
process is still time consuming and labour intensive. These limi-
tations are likely why, despite the popularity of herbal medicines,
commercial production of Echinacea rarely employs cell culture
techniques (Baque et al. 2012). In order to make tissue culture
methods viable at industrial scales, bioreactors are considered an
alternative culturing strategy. In addition to simpler technologies,
one of the newer strategies is to use temporary immersion sys-
tems (TISs), where tissues are briefly bathed in nutrient medium
then drained at specified intervals daily. Such bioreactor systems
are modular and can mass produce clonal materials in the range
of hundreds to tens of thousands of plants, making them suitable
for use in genetic improvement programs.
The simplest bioreactors are used mainly for cell suspension
cultures. However, plant cell cultures may not provide a com-
plete phytochemical profile since some compounds are only pro-
duced in differentiated cells or following environmental cues. To
deal with these limitations, several different bioreactor systems
have been developed, including gas-phase, TISs, and hybrid bio-
reactors, all of which give cultures improved access to air and
allow for the growth of differentiated organ cultures (Georgiev
et al. 2014). For example, the recently developed “Plantform”
bioreactor allowed E. purpurea tissue cultures to produce more
adventitious shoots and a greater total biomass compared to cul-
tures grown on solid media (Welander et al. 2014). These bio-
reactors use automated systems that provide a sterile
environment, and produce plants that can be ready for harvest
in just a few months. In an airlift bioreactor, both E. purpurea
and E. angustifolia adventitious root cultures consistently pro-
duce up to 10 times the biomass of field grown plants after
5 weeks, and higher levels of active phytochemicals, including
CADs, echinacoside and cynarin (Wu et al. 2007a; Jeong et al.
2009; Baque et al. 2012; Cui et al. 2013). Depending on the spe-
cies used, co-culturing adventitious roots of different Echinacea
species in balloon-type airlift bioreactors can also increase the
production of biomass and bioactives, including the synthesis of
metabolites absent from single-species cultures (Wu et al. 2017).
Whether the increase in phytochemical content is due to stress
on the plant cells in the in vitro environment, the availability of
excess nutrients in the medium, or to other aspects of the culture
environment, remains unclear.
Among the most important limitations of bioreactors is their
capacity for scale up and cost. Biomass production often
decreases at larger scales, so strategies such as medium replenish-
ment are employed to improve biomass production and phyto-
chemical content in cultured roots (Wu et al. 2007b). Although
culture vessels of up to 75,000 L have been used for suspension
culture (Ruffoni et al. 2010), scale-up tests have yet to be carried
out with new TIS bioreactors. To date, E. purpurea and E. angus-
tifolia adventitious roots have been cultured in balloon-type bub-
ble bioreactors of up to 500 L and in drum-type bioreactors of
up to 1000 L without noticeable adverse effects on growth (Wu
et al. 2007a; Ruffoni et al. 2010). Nonetheless, commercial use of
bioreactors remains costly and is limited to production of cos-
metics and high-value pharmaceuticals such as paclitaxel.
Although not yet routinely used in the Echinacea industry, bio-
reactors are becoming the standard when performing tissue cul-
ture at an experimental scale. Bioreactors offer a means of
producing standardized plant material at a scale unmatched by
field production, and the contained nature of bioreactors allows
for the use of specialized media, conditions, elicitors, growth
enhancers and year-round production. With a viable and consist-
ent propagation method in hand, the focus now shifts to improv-
ing production efficiency, economy and the quality of plant
material, in terms of both biomass and phytochemical content.
Genetic improvement
Conventional selective breeding techniques have traditionally led
to the gradual improvement of many plant species. While industry
will undoubtedly continue to develop “improved” varieties, pub-
lished Echinacea breeding studies (and patents) have focused pri-
marily on ornamentals (Ault 2002; Korlipara 2008) and reducing
seed dormancy (Qu and Widrlechner 2012). Traditional selective
breeding of Echinacea can make use of the existing genetic and
phenotypic variation in commercial and wild collected plants and
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is widely accepted by the public, including within the organic
farming industry. Conversely, direct alteration of the genome of a
plant through molecular genetic techniques is the most precise
way to modify developmental and biosynthetic processes.
Whereas public concerns will likely continue to impede the use of
Genetically Modified Organisms (GMOs), several potentially
“organically acceptable” biotechnological approaches have been
developed to modify Echinacea, including transformation with
Agrobacterium and the induction of polyploids.
Hairy root culture utilizes the natural ability of the soil bac-
terium Rhizobium rhizogenes (formerly Agrobacterium rhizo-
genes) to infect and transform plant tissue. The bacterial Ri
plasmid is transferred into the plant genome causing neoplastic
outgrowths, but incorporation of a set of genes, rolA, rolB and
rolC, causes roots to grow from the infected site instead of an
undifferentiated cell mass (Nilsson and Olsson 1997; Pistelli
et al. 2010). Hairy root cultures have several properties that are
useful for research and industry, including accelerated growth,
spontaneous regeneration of shoots, as well as chemical and
morphological similarity to the roots of a wild-type plant (Tepfer
1990; Guillon et al. 2006). Hairy root cultures of all three com-
mercially important Echinacea species produce high levels of sec-
ondary metabolites, including polysaccharides, alkylamides,
CADs and other phenolics (Trypsteen et al. 1991; Liu et al. 2006;
Wang et al. 2006; Romero et al. 2009; Pistelli et al. 2010).
Transformed roots are genetically stable, and maintain a constant
production of metabolites over a long period of time (Wu et al.
2006). The rapid growth of hairy root cultures on hormone-free
media makes them an excellent way to generate biomass quickly,
or to clonally propagate plants.
The discovery of R. rhizogenes-based hairy root transform-
ation systems in higher plants provides other opportunities to
engineer useful traits in Echinacea. Again, public acceptance of
GMOs may limit the application of this useful technology. As an
example, glufosinate-resistance and a fungal resistance chitinase
gene were simultaneously transferred into E. purpurea using R.
tumefaciens (Hanafy et al. 2010). Considering Echinacea plants
in the field are particularly susceptible to weed competition and
fungal pathogens, this study represents a useful demonstration
model. Several factors are noted to influence Rhizabium-based
transformation efficiency of Echinacea, and there is room for
optimization. For example, the efficacy of the utilized bacterial
strain is important; A4 strains were superior for transforming
Echinacea leaf explants, whereas R1000 strains worked best with
petioles (Wang et al. 2006). Overall, early development stages,
such as cotyledon tissue, are more easily transformed and sonic-
ation is up to twice as effective for producing transformants
compared to the traditional methods of wounding with a sterile
needle to enhance R. rhizogenes-mediated gene transfer (Kumar
et al. 2006). Addition of inducers to the medium during co-culti-
vation of agrobacterium with the plant tissue also improves effi-
cacy. For example, indole-3-butyric acid (IBA) increases
production of hairy roots in Echinacea by as much as 14 times
(Romero et al. 2009). Other inducers of Rhizobium-associated
gene transfer in plants (e.g., 6-benzylaminopurine, 2,4-dichloro-
phenoxyacetic acid) have been applied to Echinacea hairy root
cultures to improve transformation but their effectiveness relative
to no treatment has not been investigated empirically (Trypsteen
et al. 1991; Wang et al. 2006).
Likewise, the manipulation of ploidy can cause changes to
morphology and phytochemical content of plants. Naturally
occurring polyploids are commonly used in agriculture and
widely accepted by the public. Triploid, tetraploid and hexaploid
Echinacea plants have been developed, with tetraploids (4¼ 44)
being the best studied. In comparison to wild-type diploids, the
tetraploids studied have altered leaf, root, and flower morph-
ology, reduced seed set and dwarfed phenotypes (Nilanthi et al.
2009; Koul et al. 2010; Abdoli et al. 2013; Xu et al. 2014; Chen
et al. 2016). Tetraploid plants have similar phytochemical profiles
to wild types, but they consistently yield higher levels of CADs,
particularly in the leaves. Increased alkylamide content in the
leaves and roots of tetraploids has also been noted (Koul et al.
2010; Abdoli et al. 2013; Xu et al. 2014). The reduced biomass
production due to polyploid dwarf phenotypes currently makes
ploidy manipulation an impractical way to improve the quality
of Echinacea plant material. However, supplementing culture
media with 0.3mg/L IBA can accelerate the emergence of roots
and the increased rooting rate of tetraploid shoots in vitro
whereas IBA has no positive effect on cultured haploid or diploid
shoots (Chen et al. 2016).
Elicitation of secondary metabolites to produce high
quality plant material
Bioreactors and micropropagation techniques allow a large num-
ber of plants to be produced in a short period of time but
developing biomass with a higher concentration of bioactive
compounds ultimately makes for a more efficient industrial pro-
cess. Several methods to enhance the production of secondary
metabolites, other than genetic engineering, are currently being
studied. In particular, the use of elicitors (e.g., plant hormones,
stress signaling molecules and both biotic and abiotic com-
pounds, as well as physical injury) show promise in stimulating
the production of bioactive secondary metabolites (reviewed in
Abbasi et al. 2007a and updated in Table 1). In general, the basis
of elicitation is the activation of a plant’s defence response,
which up-regulates the production of many bioactive compounds
of commercial and industrial value. Elicitation involves either the
direct addition of signal compounds implicated in the stress
response or applying compounds that cause tissues to produce
stress signals endogenously. For example, nitric oxide (NO) is an
important signalling molecule in the plant defence response. In
adventitious root cultures of E. purpurea, adding sodium nitro-
prusside (an exogenous NO producer) to the growth medium
increased the accumulation of flavonoids and CADs (Wu et al.
2007c). Natural stress mediators can also be applied as a foliar
spray to a mature plant. Salicylic acid elicits a twofold increase
in cichoric and caftaric acid in E. purpurea flower heads, and an
almost fourfold increase of CAD in the roots when applied as a
foliar spray to field-grown plants (Kuzel et al. 2009). Elicitors
such as yeast extract stimulate the production of phenolics in
Echinacea, presumably by mimicking a pathogenic fungal infec-
tion (Li and Barz 2006). From Table 1, it should be noted that
the majority of recent elicitor research has been carried out with
E. purpurea (15/19 studies), E. angustifolia (4/19) and E. pallida
(2/19). Comprehensive screening studies that include other taxa
are warranted for biotechnology potential since it is clear that
most of the studies report increased metabolite production fol-
lowing administration of elicitors. In particular, CADs, but also
phenolics and flavonoids appear to be most responsive to elicitor
induction, likely through phenylalanine ammonia lyase (PAL)
up-regulation and defence response. Relatively few studies state
whether or not other metabolites such as echinacoside, alkyla-
mides or polysaccharides are similarly increased by application
of elicitors, so the full potential of inducing secondary metabolite
production remains unknown.
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Despite these impressive effects on phytochemical content,
elicitors can also have an inhibitory effect on growth (Baque
et al. 2012). As such, a two-phased approach – adding elicitors
only after the cell culture or plant has had time to grow – may
be necessary in order to optimize phytochemical production. For
example, by adding methyl jasmonate to the medium on day 28,
Cui et al. (2013) increased the echinacoside content in root cul-
tures of E. angustifolia threefold without reducing the biomass.
The use of chemical elicitors is particularly important in indus-
trial-scale bioreactors since the production of both biomass and
phytochemicals often decreases at large scales (Wu et al. 2007b).
Additional tests on the application of elicitors to field grown
plants would also be beneficial, since effects may differ under the
diversity of field conditions.
Commercial use of elicitors needs to balance secondary prod-
uct yields against cost and the potential residual toxicity of an
elicitor remaining in the harvested tissue. In addition, since
Echinacea is sold and regulated as a NHP or supplement (in
North America), and since there is a consumer preference for
naturally grown products, consideration should be given to the
type of elicitor used; growth hormones and stress mediators may
be preferred over abiotic elicitors and herbicides.
Other approaches to optimizing secondary
metabolite production
In addition to genetic transformation and elicitor treatments, a
number of other factors can affect the production of secondary
metabolites in Echinacea culture. Aspects of the growing envir-
onment, such as growth medium and light regime, as well as abi-
otic treatments like ultrasound or elevated UV A/B exposure that
cause physical cellular damage, have been considered for the
optimization of Echinacea products. These alternative elicitation
methods have the advantage of leaving no residues but have only
been tested in E. purpurea and need to be evaluated in other spe-
cies for their commercialization potential.
Growth medium is the basis of tissue culture, and numerous
studies have assessed what combination of nutrients produce the
best growing environment for Echinacea cultures. Depending on
the Echinacea species and tissue being cultured, the optimal
medium may differ. For instance, Wu et al. (2007a), found that
the maximum biomass of adventitious roots of E. purpurea could
be obtained on one-quarter strength Murashige Skoog (MS)
medium with 50 g/L sucrose and 1mg/L IBA, but in earlier work
with root cultures in E. angustifolia, half strength MS produced
roots with more biomass and a higher content of phenolic com-
pounds than one-quarter strength MS (Wu et al. 2006). Focusing
on alkylamide production in hairy roots, Romero et al. (2009)
reported that half-strength Gamborg’s B5 medium was best for
maintaining hairy root production and that the addition of IBA
increased growth rate by 14-fold with no impact on alkylamide
production, which was further elevated in the presence of the
elicitor, jasmonic acid.
Ultrasound treatment is a recently developed method of
increasing plant secondary metabolite content, and as such, has
not been extensively tested with Echinacea. Two studies with E.
purpurea hairy roots grown in bioreactors found that one
6minute ultrasound treatment at 40 kHz between days 15 and 20
of culture significantly increased both fresh weight and cichoric
acid content over 30 days (Abbasi et al. 2009; Liu et al. 2012).
Although the exact mechanism is unknown, the effects of ultra-
sound appear linked to an increase in PAL activity. Both studies
noted an increase in cichoric acid, with one also reporting
significant increases in anthocyanins and lignins (Abbasi et al.
2009), the biosynthesis of which are all linked to PAL enzyme
activity. Liu et al. (2012) observed enhanced CAD biosynthesis
related to increases in both rolB-regulated auxin biosynthesis and
PAL activity. Accordingly, ultrasound treatment may be less
effective at eliciting secondary metabolism using culturing tech-
niques other than hairy roots. Altered secondary metabolism
may also result from ultrasound-induced physical damage to the
cells, causing a general stress response. Indeed, Liu et al. (2012)
noted that stimulating hairy roots with ultrasound caused a sig-
nificant decrease in biomass accumulation, likely indicating cell
damage or stress. This method of elicitation is very simple,
requires no chemical input, and leaves no residues, and therefore
merits study with other forms of tissue culture as well as with
other species of Echinacea.
Light is essential for the growth of plants and for the regener-
ation of shoots in culture. While callus, root and suspension cul-
tures are generally maintained in the dark, exposing these
cultures to light can have beneficial effects on their phytochem-
ical content. Continuous light for 14 days significantly increased
CAD levels in cell suspensions of E. angustifolia (Guarnerio et al.
2012). Similarly, hairy root cultures of E. purpurea incubated
under continuous light showed not only an increase in CADs
but also thicker roots that developed a purple colour, indicating
the production of anthocyanins. Increased CAD and anthocyanin
production have been linked to the activation of PAL enzymes,
although the mechanism of PAL activation by light is unknown
(Abbasi et al. 2007b). Enhanced production of CADs and antho-
cyanins was also observed by Abbasi et al. (2012) with the appli-
cation of gibberellic acid to E. purpurea hairy roots. If light
treatment can produce effects comparable to certain elicitors,
then light-induced effects on secondary metabolite production
warrants further investigation. In particular, it would be interest-
ing to test different wavelengths, intensities and light/dark
regimes to determine if the same or greater effects can be
achieved without continuous bright light.
As has been demonstrated with other species, an extension of
abiotic light treatment is the recently reported application of ele-
vated ultraviolet light during Echinacea callus and cell culture to
alter secondary compound formation. Manaf et al. (2016) tested
the effects of UV-B radiation on E. purpurea cultures for short
periods in varying exposures. The effects were variable, depend-
ing on the dose–time response. All UV-B treatments increased
caffeic acid and antioxidant activity of callus cells and growth
parameters, total phenols content and antioxidant activity of cell
suspensions in a dose-dependent manner. The same group also
tested both types of Echinacea cultures with varying doses of
UV-C with similar results (Abd El-Aal et al. 2016).
Endophytes, microbial species that colonize plants without
causing disease symptoms, are associated with almost all plants
on Earth. Endophytes can be isolated from all parts of field-
grown Echinacea, including the seeds, leaves, stems and roots.
The most common fungal genera in the roots of Echinacea
include Glomus, Cladosporium, Alternaria and Fusarium (Lata
et al. 2006; Araim et al. 2009; Zubek and Błaszkowski 2009; Rosa
et al. 2012; Moszczynska et al. 2013). Endophytes form symbiotic
relationships with the plant, using photosynthesized sugars for
nutrition, in turn helping the plant to uptake nutrients (particu-
larly nitrogen), and defend against herbivores and pathogenic
microbes (Arnold and Lutzoni 2007; Aly et al. 2011). Plants
colonized with endophytic fungi are less often infected by patho-
gens, show increased growth rates, and have improved stress tol-
erance (Saikkonen et al. 1998; Lata et al. 2006; Araim et al. 2009;
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Zubek and Błaszkowski 2009; Gualandi et al. 2014). Notably, col-
onization with arbuscular mycorrhizal fungi impacts phytochem-
ical content, increasing CADs in the roots of E. purpurea (Araim
et al. 2009). The mechanism of this effect in Echinacea is
unknown, and could potentially be attributed to increased uptake
of nutrients, elicitation of the plant’s defense response (including
PAL up-regulation), or production of bioactive compounds by
the endophytes, among other explanations. Nevertheless,
manipulation of field grown plants to encourage specific endo-
phytes may increase yields of secondary metabolites.
Future directions in Echinacea research and industry
The development of new biotechnologies provides many options
for improving Echinacea NHPs and other products. Moving for-
ward, the benefits and drawbacks of each of these approaches
should be considered in terms of improvements in yield, opti-
mization and standardization of phytochemistry, propagation
efficiency, cost, public perception and ease of use at scale.
As previously noted, bioreactors allow for the rapid growth of
cultures and produce cloned propagules, ensuring consistent
phytochemical content. In vitro culturing reduces contamination
by plant pathogens and other microbes and is less labour inten-
sive than field cultivation. However, individual plant tissues may
not produce a full range of phytochemicals, and biomass produc-
tion may be limited by culture techniques and equipment.
Despite reduced labour, the cost of bioreactor culture is high, as
it requires specialized materials, facilities and personnel training.
Genetic engineering has the potential to improve plant mater-
ial in several ways but has multiple drawbacks making it cur-
rently impractical for use in the Echinacea industry. Genetic
transformation may not improve propagation efficiency, does not
necessarily increase yield (except hairy roots), and does not guar-
antee more standardized plant material. Most importantly, the
NHP market may not readily accept the use of GMOs. Despite
the fact that ploidy variation and hairy root disease occur natur-
ally, market research should precede employment of such tech-
nologies. Genetic transformation is useful to study the growth
and biochemistry of plants but, since elicitors and selective
breeding can produce similar improvements in yield and quality,
genetic engineering may not be the best option for industry.
Elicitors are easy to use, do not change propagation efficiency,
and can be applied to either organ cultures or field-grown plants.
Elicitors effectively improve phytochemical content and some,
such as IBA, can increase yield. Other optimization techniques
such as ultrasound, UV and ozone (abiotic elicitors) can simi-
larly produce increases in phytochemical content in tissue cul-
ture. Administering ultrasound is inexpensive, simple to use, and
will not result in toxic residues, but improper use may lead to
decreases in yield and ultrasound technologies have not yet been
adapted for use with field cultivation.
In general, bioreactors may have advantages for propagating
cultivars through rapid production of cloned propagules.
However, a focus on the growth of whole plants for the produc-
tion of herbal medicines seems the most beneficial overall cur-
rently. Whole plants are technically less complicated to maintain
and can produce more complete phytochemical profiles. Even
though the price of tissue culture has come down, it is still not
feasible to grow full plants to maturity at industrial scale using
bioreactors. Therefore, it may be best to use tissue culture as a
method of propagation followed by growing cloned plantlets in
more traditional field, greenhouse or hydroponic systems.
Chemical elicitors are most effective for increasing
phytochemical content, and can be included in the production
process, along with control of light regimes during indoor pro-
duction. Such models would take advantage of both the benefits
of tissue culture and the existing cultivation space.
Growing entire plants would also be worthwhile since each
part of the plant has unique properties that can be used for dif-
ferent kinds of products. Echinacea supplements on the market
today are most often an extract of the roots, flower heads or
both, with the leaves of E. pallida occasionally included. Finding
uses for the remaining plant parts and developing alternate
applications of Echinacea is the logical next step for research and
industry. There is very little information available on the phyto-
chemical and medicinal properties of rare Echinacea species,
however in vitro culturing technology may now allow for the
growth and study of these species without disturbing natural
populations. Non-commercial Echinacea species may yield com-
pounds that are not present in E. purpurea, E. angustifolia or E.
pallida (Binns et al. 2002b)
Emerging market opportunities for Echinacea include addi-
tives in animal feed. Studies on chickens, pigs, rainbow trout and
horses have consistently found that Echinacea feed additives
improve immune activity, including increases in lymphocytes,
phagocytosis and globulin content (Williams and Lamprecht
2008; B€ohmer et al. 2009; Grashorn 2010; Dehkordi et al. 2011;
Oskoii et al. 2012). The addition of Echinacea to feed or water
also improved the efficacy of vaccines for fowl influenza, swine
erysipelas and Newcastle disease virus in fowl, increasing the
antibody titers in livestock (Maass et al. 2005; B€ohmer et al.
2009; Dehkordi et al. 2011; Najafzadeh et al. 2011). Reducing the
incidence of infection in livestock improves growth rate and
decreases the chances that pathogens will be transferred between
animals or to humans. Restrictions on the addition of synthetic
antibiotics to animal feed in several countries may soon expand
the market for herbal medicines in the livestock industry. The
only negative reports to date on Echinacea feed additives were
minor allergic reactions in horses (Williams and Lamprecht
2008). Addition of E. purpurea to feed did not significantly alter
growth characteristics of quail (Sahin et al. 2012). Nevertheless,
residual Echinacea bi-products from human health applications
should be explored as value-added animal feed supplements,
including uses for leaves, stems and seed cobs. More research is
needed in order to determine the most effective form, delivery
method, and dosage for employing Echinacea as a commercial
feed additive.
Echinacea seed also may have additional market potential.
Only a fraction of the seed produced by Echinacea is required
for traditional plant propagation. Expanded use of tissue culture
also means that additional seed could be harvested solely for use
in NHPs. Indeed, use of seeds may add value to Echinacea crops
since seeds are generally not incorporated into commercial prod-
ucts. Seed oils from all three commercial Echinacea species are
very nutritious, being high in oleic acid, palmitic acid, linoleic
acid, vitamin E (28–85mg/100 g oil) and other bioactive com-
pounds (Oomah et al. 2006; Vandyshev et al. 2009; Parsons et al.
2018). Seed oil yields range from 13 to 23%, depending on spe-
cies and seed size, with E. purpurea seeds generating the greatest
volume and highest quality of oil. The seeds of E. purpurea and
E. angustifolia contain 0.75 and 1.06mg of bioactive alkylamides
per gram, respectively (He et al. 1998). Oils from other members
of the Asteraceae family, such as sunflower oil, are commonly
used for both dietary and industrial purposes.
Echinacea essential oil also contains a number of medicinal
compounds including germacrene-D, a sesquiterpine
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hydrocarbon with antimicrobial properties, and alkylamides,
which can be detected by the tingling sensation caused on the
tongue when the oil is tasted (Mirjalili et al. 2006; Oomah et al.
2006). E. purpurea essential oil significantly reduced inflamma-
tory swelling in mice and rats, and decreased the levels of cyto-
kines IL-2, IL-6 and TNF-a in the blood (Yu et al. 2013). These
effects are also characteristic after administering alkylamides in
animal models. With further research and the development of
standard extraction procedures, Echinacea seed oil and essential
oils also have the potential to become successful product lines
within the Echinacea industry.
Echinacea is almost exclusively sold as an immune-boosting
supplement in the contemporary US market. However, the devel-
opment of micropropagation, bioreactors and elicitors make it
possible to take advantage of other bioactivities. Extensive study
demonstrates that Echinacea extracts have antibacterial, antiviral
and antifungal activities (Merali et al. 2003; Sharma et al. 2008;
Mir-Rashed et al. 2010; Hudson 2012). Echinacea alkylamides
were shown to have an interesting mode of action through per-
turbing the fungal cell wall/membrane complex – an ideal anti-
fungal target that is unique to fungi (Cruz et al. 2014). Of those
tested, one structural class of alkylamides, the diynoic alkyla-
mides, showed the greatest antifungal and cell wall disruption
activities. The natural variability in the phytochemical profiles of
Echinacea plants, combined with high-throughput screening and
use of elicitors make it possible to quickly select and propagate
various cultivars with unique metabolic profiles, tailored to spe-
cific functions such as production of antifungals. Alternatively,
Echinacea varieties could be selected for large seeds with nutri-
tious seed oil, or modified to produce more CAD in the flowers,
which could be used as a dietary supplement. The roots and
flowers of cultivars rich in alkylamides and cichoric acid could
be used to make antibacterial face washes, shampoos or creams.
Like other members of the Asteraceae family, Echinacea contains
some polyacetylene compounds that are phototoxic, but these are
unstable and could be inactivated by minimal processing (Chen
et al. 2010; Chen et al. 2013). Echinacea leaves, high in vitamin
C and phenolic metabolites, could also be marketed as a NHP.
This potential diversity of uses has yet to be harnessed by
the industry.
Moving forward, a combination of tissue culture, chemical
treatments and traditional field cultivation will likely be used to
generate a new higher standard of production and phytochemical
quality. These advances will provide the opportunity to establish
a greater variety of Echinacea products to keep up with ever-
expanding market opportunities.
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